Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer Clinical research trials and Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer. Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer clinical trial. Test subjects typically receive the most effective healthcare possible for their Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "C" Clinical Trials Conditions > Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer

Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer



Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer

For Condition: extensive stage small cell lung cancer,Recurrent Small Cell Lung Cancer
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Beckman Research Institute
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chloroquinoxaline sulfonamide in treating patients who have small cell lung cancer that has not responded to platinum -based chemotherapy.
Details: OBJECTIVES: I. Determine the efficacy of chloroquinoxaline sulfonamide in patients with platinum-refractory small cell lung cancer. II. Determine the toxic effects of this drug in these patients. PROTOCOL OUTLINE: Patients receive chloroquinoxaline sulfonamide IV over 1 hour once a week for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed until death. PROJECTED ACCRUAL: A total of 12-38 patients will be accrued for this study within 3-10 months.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed platinum-refractory small cell lung cancer; No response or progression during or within 6 months of completing platinum based therapy - Measurable disease - No symptomatic brain or leptomeningeal metastases --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: See Disease Characteristics; No more than 2 prior chemotherapy regimens; At least 3 weeks since prior chemotherapy and recovered - Endocrine therapy: No concurrent corticosteroids to control symptoms of brain and/or leptomeningeal metastases - Radiotherapy: At least 4 weeks since prior radiotherapy; No concurrent radiotherapy to measurable lesions - Surgery: Not specified - Other: No concurrent hypoglycemic agents (including insulin) --Patient Characteristics-- - Age: 18 and over - Performance status: SWOG 0-2 - Life expectancy: At least 12 weeks - Hematopoietic: Granulocyte count at least 1,500/mm3; Platelet count at least 100,000/mm3; No hemolytic anemia - Hepatic: Bilirubin normal; AST no greater than 2.5 times upper limit of normal - Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min - Cardiovascular: No history of cardiac arrhythmias - Other: No other active malignancy requiring concurrent treatment; No allergy to sulfonamides; Not pregnant or nursing; Negative pregnancy test Fertile patients must use effective contraception
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
PrimoLara,  Study Chair,  Beckman Research Institute

Cancer Center and Beckman Research Institute, City of Hope
Duarte,  California,  91010-3000
United States
 

University of California Davis Cancer Center
Sacramento,  California,  95817
United States
 

USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles,  California,  90033-0804
United States
 


Additional Information:
Study ID Numbers:  CDR0000068401;  NCI-57,CHNMC-PHII-26
Study Start Date: December 2000
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00008372

Other Extensive Stage Small Cell Lung Cancer Studies:
1. Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.

2. Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer

3. Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer

4. Cisplatin Combined With Either Irinotecan or Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

5. Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Related Studies:

Other extensive stage small cell lung cancer Clinical Trials
Other California Clinical Trials
Other Duarte Clinical Trials

Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer
Modify your Search

  Other extensive stage small cell lung cancer Clinical Trials
  Other California Clinical Trials
  Other Duarte Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103